**Toll Like Receptors Play a Role in General Immunity, Eye Infection and Inflammation: TLRs for Nanodelivery**

Jagat R. Kanwar1*, Shu-Feng Zhou2, Sneha Gurudevan1, Colin J. Barrow1 and Rupinder K. Kanwar1

1Nanomedicines-Laboratory of Immunology and Molecular Biomedical Research (LIMBR), Centre for Biotechnology and Interdisciplinary Biosciences (BioDeakin), Institute for Technology and Research Innovation (ITRI), Geelong Technology Precinct (GTP), Deakin University, Piggots Road, Waurn Ponds, Geelong, Victoria 3217, Australia

2Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, 12901 Bruce B Downs Blvd., Tampa, FL

**Abstract**

Dendritic cells [DCs] are potent antigen presenting cells [APC], which plays a vital role in immune system by detecting and capturing pathogens in the body. DCs perform a pivotal role in induction of T cell response. Regulation of immune response can be achieved by specific antigen [Ag] delivery to DCs. A delivery system that can efficiently target and present Ags to DCs for the purpose of anti-tumour activity is currently a topic of significant research interest. DCs are receiving attention due to their key role in anti cancer host response and due to their adjuvant property in tumour vaccines. Role of toll like receptors [TLRs] in innate immune system and their part in eventual stimulation of adaptive immunity is exploited to develop vaccines. TLR agonists in conjugation with vaccines are shown to increase therapeutic efficacy in some cases. TLRs also play a vital role in protecting the cornea from invading pathogens. Due to adverse effects in the treatment of ocular inflammations, cancer and in viral infections, an alternate approach such as the use of TLRs will solve the inquisitive question regarding side effects. The intended delivery is attained by the use of nanoparticles which in turn leads to prolonged half-life in the body. Co-delivery of Ags, TLRs and immunomodulators using nanoparticles has been demonstrated to elicit potent cellular immune responses and are currently under development of clinically applicable immunisations and vaccines.

**Introduction**

In spite of all the efforts to suppress the spread of infectious diseases and cancer by the biomedical sector, they still represent the major cause of death. According to world health organisation [WHO], cancer is responsible for one third of lost years of life [1]. Most cancers are treated by combination of standard therapies like surgery and chemotherapy. Conventional therapies not only target tumors cells but also healthy cells as the drug does not discriminate the cell types. To overcome these obstacles, targeted nanomedicine is designed for the delivery of drugs selectively to tumor cells. Therapeutic vaccination against tumors proved far more stringent than prevention. The goldilocks approach of establishing tumor immunity with the molecularly designed nanoweapons would aid in the homeostatic induction of immune cells and other host effector molecules. Toll like receptors [TLRs] are one such crucial sensors of innate immune system identified as key targets in tumor immunology. TLRs are pattern recognition receptors [PRR] which recognise antigens [Ag] and initiate the immune cell cascade. The use of TLRs as molecular targets for intensifying immune response provides a substantial advance in the field of therapeutics. Pathogen mimicking nanoparticles capable of interacting with dendritic cells [DCs] in conjunction with TLR regulates the immune system. Amalgamating nanocarriers with the agonists increases the levels of proinflammatory cytokines, chemotactic factors and type 1 Interferon [IFN]. This response eventually elevates adaptive immunity and further vaccine responses, to combat malignant cells. On the basis of pharmacokinetics profile, either agonist or antagonists are used therapeutically for various diseases. Clinical trials are imperative in using these agents to collect safety and efficacious data for health interventions. This paper will explore the horizons of TLR utilisation in cancer biology, corneal inflammations and in viral infections to up-regulate immunosuppressive state of humans.

**TLR and immune system**

The innate immune system relies on the recognition of simple molecules and regular patterns displayed by pathogens and many microorganisms which are not seen on the body’s own cells [3]. These structures, known as pathogen associated molecular patterns (PAMPs), are recognised by receptors known as PRRs. The innate immune system as well as the adaptive immune system relies heavily on the function of PRRs. However, recognition of non-pathogenic and commensal microflora by PRR is largely unknown [4]. Presumably, compartmentalization (confinement of commensal microflora to luminal side of intestinal epithelium), transforming growth factor (TGF-β) and interleukin (IL-10) play an important role in this process. PAMP’s are highly conserved throughout the evolution and are less destined for mutation since they are vital for survival of microbes. Three main features of PAMPs make them ideal targets for innate immune system. First, they are produced only by microbes and not by host cells. Second, they are invariant between microorganisms of a given type.
class and thirdly, PAMPs are essential for survival of the microorganisms [5]. There are a variety of different types of PRRs, where TLRs are one major group. TLRs belong to type I transmembrane receptors characterised by the presence of leucine-rich repeat domain (LRR) and an intracellular Toll/IL-1 receptor domain (TIR). They appear to be one of the most conserved components of the immune system with basic signaling receptors for the innate immune stimulation. Its expression is ubiquitous from epithelial to immunocompetent cells [6,7]. Associated with the TIR domain are the presence of five adaptors myeloid differentiation MyD88, MyD88-adaptor like (MAL), TIR-domain containing adaptor protein inducing IFN-β (TRIF), TRIF related adaptor molecule (TRAM) and sterile α- and armadillo motif containing protein (SARM) [8]. These adaptor molecules activate intracellular molecules including protein kinases to orchestrate the inflammatory response [9]. The human TLR family is known to consist of 10 members with this number likely to increase as relatively little attention has been given to them in the past [3,10]. TLR 1 and TLR 2 dimerization responds to triacyl peptides [11] whereas, TLR 2/TLR 6 recognizes diacyl peptides [12]. TLR 2 in combination with lectin receptors enables the recognition of fungal cell wall component zymosan [14]. Double stranded RNA and some synthetic RNA motifs are ligands for TLR 3 [13]. TLR 4 serves as a specific receptor for lipopolysaccharide (LPS), the most powerful microbial stimulant of innate immunity. By promoting the release of inflammatory cytokines, LPS also mobilize the innate and adaptive immune response [15]. TLR 5 has been shown to recognize conserved domains of flagellin (a monomeric constituent of flagella). TLR 5 is reported to be present on basolateral side of intestinal epithelial cells and in sub epithelial compartment necessitating the balance of homeostasis at the mucosal layer [16]. Down the lane, TLR 7, TLR 8 and TLR 9 are reported for recognition of ssRNA from viruses. The host ssRNA are not recognized as foreign by TLR 7/8 due to the subcellular expression of these TLRs in the endosomal compartment. TLR7/8 also recognizes synthetic compounds: imidazoquinolines used for treating genital warts and loxoribine as an immunostimulant [17]. TLR 9 is a receptor of unmethylated CpG DNA motifs which are the characteristics of a bacterial genome [18]. CpG motifs with GAGTT sequence stimulate mouse TLR 9 while with the core sequence GTCGTT optimally induce human TLR 9 [19]. TLR 11 gene present in animals are resistant to uropathogenic strains of E.Coli. Human kidney also appears to contain TLR 11 gene yet the protein is not expressed [20]. Animals are shown to explicit TLR 12 and TLR 13 with no counterpart expression in the synthetic production is highly complex. Hence the focus is diverted towards development of synthetic agonists. The synthetic component derived from Staphylococcus aureus, 16 S-[2, 3-bis (palmitoyl)propyl] cysteine (Pam2) lipopeptides is shown to activate DCs and natural killer [NK] cells for the production of TNF and interleukin (IL-12) [24]. Though the use of BCG stands as an age old concept, its clinical usage is limited since the synthetic production is highly complex. Hence the focus is diverted towards development of synthetic agonists. The synthetic component derived from Mycobacterium bovis (Bacille Calmette-Guerin vaccine) has been used as an adjuvant since, the cell wall of this bacterium comprises of NOD-2 agonist muramyl dipeptide. The inflammatory response to BCG antigens is processed via TLR 2 and TLR 4. Lipoarabinomannan and lipomannan from this bacterium activates the immune cells for the production of TNF and interleukin (IL-12) [24]. Though the use of BCG stands as an age old concept, its clinical usage is limited since the synthetic production is highly complex. Hence the focus is diverted towards development of synthetic agonists. The synthetic component derived from Staphylococcus aureus, 16 S-[2, 3-bis (palmitoyl)propyl] cysteine (Pam2) lipopeptides is shown to activate DCs and natural killer [NK] cells for the production of interferon [IFN-γ] [25]. With the incorporation of RGDS peptide for the effective cell penetration, their use as an adjuvant has surpassed the disadvantages of commercial adjuvants in use. The Pam2 lipopeptides have two palmitoyl bases attached to two separate peptide sequences for the determination of TLR 2 agonist activity [26]. The mucosal adjuvant effect of TLR 3 dsRNA agonist produces high concentration of IgA and also protects from the recurrent viral infections. Due to the toxicity profile of poly (I: C), a chemically modified form [PolyL:C, U ] of the above formulation was synthesized. Additionally, PolyL:C, U [AMPLIGEN] is used as an adjuvant for mucosal vaccine for avian H5N1 virus [27]. In regard to tumor therapy, poly (I: C) has been used as a cancer adjuvant vaccine since they can effectively activate DCs and NK cells. The main function of poly (I: C) is to boost the maturation of DCs for further priming and clonal expansion of antigen specific T cell response. Interestingly, the TLR 3 agonist acts through diverse accessory molecules rather than acting via DCs alone [28]. A recent study by McCartney showed the involvement of NK cells, IFN-α and IL-12 associated with the TLR 3 signaling pathway activation through poly (I: C) agonist [29]. Cervarix, a vaccine against human papilloma virus is formulated with monophosphoryl lipid A [MPL], a TLR 4 targeted adjuvant for promoting the immune response. The clinical grade form of MPL has low toxic profile of about 0.1%. [30]. TLR 5 agonist, flagellin is used as an adjuvant for the delivery of recombinant hemagglutinin. The use of flagellin to adjuvant influenza vaccines via TLR 5 innate immune pathway trigger a cascade of multitudinal transcriptional events responsible for adaptive immunity. [31,32]. Commonly used agonists for TLR 7 are imiquimoid and resiquimod. Very recently, a...
guanosine analog 7-allyl-7,8-dihydro-8-oxo-guanosine (loxoribine) has been identified as a TLR 7 agonist. They activate plasmacytoid DCs and B cells for the induction of IFN-α and IFN-regulated cytokines [33]. A very similar pattern of activating myeloid DCs, monocytes and monocytes derived DCs for the release of TNF-α, IL-12 and macrophage inflammatory protein – 1 α is through TLR 8 agonist – VTX-2337 which is in phase I study. Due to its high adjuvanting property, it has been used to treat solid tumors or lymphoma [34]. Synthetic and natural oligodeoxynucleotides containing specific motifs of CpG dinucleotide are potent immunostimulatory agents for activation of TLR 9 pathway [35]. They directly induce the differentiation of B cells into antibody secreting plasma cells. On the other hand, release of IFN-α from immature DCs activates NK cells for the action of tumor cell lysis. Mature DCs capture the released tumor Ags and process it through major histocompatibility complex [MHC] which in turn leads to the migration of DCs to lymph nodes for the delivery of processed Ags to lymphocytes initiating T-helper response [36]. The activity and safety of these molecularly defined adjuvants and formulations has provided support for the concept of antitumor and antiviral immunity with reduced adverse effects.

**Sorting of toll signals via TLR adaptors**

The downstream pathways of TLR signaling require two major adaptor proteins MyD88 and TRIF. The utilisation of TIR domain containing adaptor protein or Mal [TIRAP] and TRIF related adaptor molecule [TRAM] has been associated with TLR 2 and TLR 4. Several transcriptional regulations involving nuclear factor [NF-kb], activator protein-1 [AP-1], interferon regulatory factor 3 and 7 [IRF] constitute pleiotropic effects with tightly regulated gateways for gene modulation [37]. In regard to MyD88 dependent pathway, the adaptor molecule MyD88 possesses TIR domain in C terminal and death domain in N-terminal portion. Associating with TIR domains of TLRs, MyD88 recruits IL-1 receptor associated kinase (IRAK). After phosphorylation it interacts with TIRN receptor associated factor [TRAP 6] for the activation of two crucial signaling pathways JNK and NF-kb [38]. In the case of MyD88 independent pathway, LPS induces the activation of NF-kb and JNK through TLR 4 stimulation. Precisely, IFN-induced protein 10 [IP-10] and glucocorticoid attenuated response gene [GARG 16] were initiated for the induction of immune cascades. They also augment surface activation markers like CD40, CD80 or CD 86 in dendritic cells [39]. The molecular stack of 232 aminoacid molecule MyD88 possesses IL-1 receptor associated kinase (IRAK). After phosphorylation it interacts with TIRN receptor associated factor [TRAP 6] for the activation of two crucial signaling pathways JNK and NF-kb [38]. In the case of MyD88 independent pathway, LPS induces the activation of NF-kb and JNK through TLR 4 stimulation. Precisely, IFN-induced protein 10 [IP-10] and glucocorticoid attenuated response gene [GARG 16] were initiated for the induction of immune cascades. They also augment surface activation markers like CD40, CD80 or CD 86 in dendritic cells [39]. As the molecular stack of 232 aminoacid molecule MyD88 possesses TIR domain in C terminal and death domain in N-terminal portion. Associating with TIR domains of TLRs, MyD88 recruits IL-1 receptor associated kinase (IRAK). After phosphorylation it interacts with TIRN receptor associated factor [TRAP 6] for the activation of two crucial signaling pathways JNK and NF-kb [38].

**Corneal immunity**

The delicate visual organ that is responsible for vision is highly vulnerable to immunological inflammation and microbes. The features that account for the constructive action of vision are 1) ocular barriers 2) absence of lymphatic drainage pathways 3) presence of immunomodulatory factors and 4) possession of APCs. Presence and utilisation of TLRs for improving ocular immunity will quench the thirst for corneal haze.

**Corneal TLR**

Cornea is an ideal model for evaluating in vivo angiogenesis in cancer. The introduction of targets initiates angiogenesis, thus providing a platform for tumour study [42]. Rabbit eyes are excellent prototype for such studies. Recently research on mice eyes has also been initiated. Basically, cornea is a transparent, dome-shaped surface, with two specialized function i) protective barrier between the external environment and internal milieu, ii) constitutes the main refractive element of visual system [42,43]. It is made of three major layers: epithelial, stromal and endothelial cells. Corneal epithelium extends a barrier, and restricts entry of pathogens into eye [43]. It has an ability to detect and fight microbial pathogens [44-46]. Nonetheless, corneal innate immunity involves many other components such as keratocytes, corneal fibroblasts, langerhans cells (dendritic cells) and immunoglobulins (IgG and IgA) [45]. It has been demonstrated that injury or infections to the cornea triggers an immune reaction which leads to recruitment of polymorphonuclear cells, lymphocytes, and fibroblasts following the release of chemotactic factors such as IL-8 and cationic antimicrobial protein of 37 kD from corneal epithelium (Figure 1). Expression of TLR 1 to 10 is observed in corneal epithelium from patients with ocular diseases and also from human cadavers. However, not all subjects express all the TLRs. TLR 7 and TLR 8 expression is very low in some cases [46]. The constitutive as well as inducible expression of various TLRs such as TLR2, TLR3, TLR4, TLR5, TLR9 and TLR10 have been seen in corneal epithelium in vitro and in vivo [44-46]. Corneal expression of TLRs is mediated during inflammatory disorders such as atopic keratoconjunctivitis, sjogren’s syndrome as well as during bacterial, viral and fungal infections [47]. TLR2 and TLR4 expression in cornea functions as a gram-positive and gram-negative bacteria [Pseudomonas aeruginosa] sensor [48]. Flagellin protein present in flagella[Pseudomonas] is a ligand for TLR 5 [49]. Lipoprotein also binds the TLR2/1 dimer albeit from mycoplasma [50]. TLR7 has been shown to recognize Herpes Simplex Virus [HSV-1] infection and likely involved in corneal innate immune responses in herpetic keratitis [43]. TLR9 recognises CpG rich DNA viruses as well as gram negative and gram positive bacteria [51]. Upregulation of defensins, small peptide that target bacterial cell wall has been recognised after activation by TLR, thus solidifying the importance of TLR [43]. Although the corneal inflammatory response via TLR signalling is vital for efficient removal of pathogenic microbial agents, an inadequately regulated proinflammatory cytokine production may result in inflammatory responses which would lead to corneal scarring and loss of vision altogether. In some cases, constant activation of TLR leads to the other corneal inflammatory conditions such as dry eye syndrome and allergy. Thus a TLR decelerator is necessary to curtail the proinflammatory state. Although information regarding this indispensable process is scarce, negative regulators of TLRs induce single Ig IL-1 related molecule [SIGIRR] and ST2 [member of TIR family which do not activate NF-kb] [52]. These two molecules act by impounding on MyD88 and IRAK [IL-1R associated kinases] [47]. SIGIRR or ST2 blockade leads to serious bacterial corneal diseases. This strongly suggests that even though TLR signaling is necessary to fight against pathogens, if the signaling activity is unchecked by SIGIRR or ST2 serious corneal injury develops. This poses a most formidable conundrum of how to modulate TLR signaling in such a manner so as to maximize surveillance and disposal of foreign invaders while curbing potential damage to self. Ocular epithelial cells are very selective in...
responding to microbial products by discriminating the pathogenic bacteria from non-pathogenic ones. Corneal opaqueness which is often referred as corneal haze results in patients who are treated for myopia, hyperopia and astigmatism. Sometimes it disappears within 6-9 months but not in all cases. Wolbachia, an endosymbiotic bacteria lives in a parasite Onchocerca volvulus which mainly infects Africans [53]. During these infestations, the parasite resides in subcutaneous nodules and releases millions of microfilariae which migrate to anterior chamber of eye. As a result of immune defense, several chemokines and cytokines are released to combat the infection. As a result of the release of CXCR2, a chemokine produced by stromal cells, neutrophils are recruited to the site [54]. This phenomenon results in the transformation of fibroblast present in stromal layer to myofibroblast with high expression of smooth muscle actin. These myofibroblasts accumulate extracellular matrix and matrix metalloproteins in the infection site to alter biophysical environment of the infectious site. Corneal opacity is also caused by decreased expression of corneal crystallins by activated fibroblasts [55]. A Major threat to aboriginals in Australia is Trachoma infection which leads to morbidity and blindness (Figure 1). In most cases, active trachoma in the conjunctiva heals without any loss of vision. On the contrary, chronic infection leads to block of lachrymal ductules leading to loss of tears thus creating a platform for secondary infections. Apparently vaccines produced only short term immunity and hence TLR agonist can be used against this infection. No particular synthetic TLR agonist has been synthesized till now for Trachoma yet LPS can be an alternate agonist to some extent [56-58]. Approach to corneal haze with nanotechnology is in its infancy. Various nanoformulations comprising TLR agonist and antagonists have been used. Studies by Ueta clearly show that corneal epithelial cells engage TLR 3 to produce proinflammatory factors in response to poly (I: C), a viral mimic [59].

**Enhancement of tumor immunity by augmenting DCs**

Current cancer vaccine suffers from poorly quantifiable T-cell response and immunosuppressive tumour microenvironment. So there is a need to improvise the vaccine engineering such that lasting
immune response is acquired with reversal of immunosuppression in tumour environment. Customized nanoparticles are designed to meet the expectations of targeted delivery with prolonged half-life in the body [55]. Nanotechnology based drug delivery uses a variety of nanovectors including liposomes, micelles, dendrimers, protein nanoparticles, ceramic nanoparticles, polymeric nanoparticles and metallic nanoparticles [60,61]. These are used to carry and deliver drugs specifically to the site of tumour. These drug delivery systems generally consist of three parts; the core material, a therapeutic drug and surface modifiers [62]. The surface engineering involves functionalisation with ligands such as peptides, aptamer, antibodies, nucleic acids or small molecules in order to increase specificity and efficacy of treatments [63]. Anti tumour drugs with low molecular weight tend to distribute throughout the body by systemic circulation, yet diffuse from the cancerous tissue easily reducing the residence time and eventually get eliminated by renal filtration. Therefore, high molecular weight polymer like polyethylene glycol [PEG] is conjugated to drug molecules, so that the drug tends to stay within the leaky vasculature of tumour cells. Non PEGylated particles have short retention time in the systemic circulation [64,65]. Tumour targeting can be passive or active [66]. Passive targeting takes advantage of leaky endothelial cells, which are from fast growing cancerous tissue, so that nanoparticles can enter and accumulate in the interstitial space. This method is more primitive as it relies on diffusion [62]. A more favourable approach can be achieved if the nanoparticles specifically target tumour cells and are activated once the target is reached. Active targeting involves the conjugation of drug to the nanoparticle of a targeting constituent to provide specific accumulation of nanoparticle at the tumour site [67,68]. Tumor cells overexpress receptors or Ags, which can be helpful for the efficient uptake of drugs via receptor-mediated endocytosis. Various ligands such as proteins, antibodies, carbohydrates, nucleic acids and aptamers are used for targeted delivery [69]. Imaging the nanoparticles is the next hurdle in the field of therapeutics. The development of multifunctional nanoparticles in which drug delivery, sensing and imaging capabilities are integrated is known to be a powerful system. Nanoparticles are targeted to APCs for enhancement of tumor immunity. Specific targeting of DCs through nanoparticles enhances the proliferation of Ag specific CD8 and CD4 cells [70,71].

After phagocytosis, when nanoformulation gets dislodged from endosomes, Ag or drug is released. The cytokotic Ag is then recognised by MHC class I molecule on DCs leading to cross presentation. Hamdy et al. examined that co-delivery of ovalbumin and 7 acyl lipid A in PLGA-nanoparticle augmented DC maturation and ovalbumin-specific CD4+ and CD8+ T-cell proliferation responses. Following up this study, encapsulated ovalbumin and TLR 9 in PLGA showed tumor regression of about 80% in animals with ovalbumin expressing B16 melanoma. Mutual activation of DC and NK cells in the presence of TLR agonist forms the basis for tumour suppression [72]. Pham et al experimented in TLR 4 agonist to enhance the maturation of DCs by NK cells. Lower doses of cyclophosphamide and IL-12 promoted the articulation of tumor specific CTL and several co-stimulatory molecules. This vaccine model was found to inhibit mouse colon cancer [CT-26] [71]. A research group headed by Conforti et al. [50] revealed that TLR 3 stimulates the epithelial cells of tumour to initiate chemokine cascade. This fundamental knowledge gave rise to use of poly (A:U) to activate CCL5 and CXCL10 [Chemotactic cytokines]. Systemic administration of poly (A:U) displayed immunoadjuvant effect through TLR3/TLR7. Both these TLRS are essential for clonal selection of Ag specific CD8+ T cells. When poly (A:U) is combined with vaccine or chemotherapy the anti tumour titre was elevated [73].

Cell specific targeting via mannose receptors

In an early study, cell specific ligands for targeted drug delivery were investigated using mannan coated nanoparticles [74]. DCs and macrophages both express mannose receptors (ManR). ManR are PRRs which recognise glycoproteins present in fungal cell walls, viruses and in prokaryotes. Man is a scavenging receptor which recycles back to the cell surface where it can be employed in consecutive cycles for internalisation. The nanoparticles coated with mannan ligands can be used for targeting APCs to enhance the particle uptake for increasing the anti tumour titre [74]. Without addition of the mannose receptor ligands on the nanoparticles, Ag recognition is limited with low T cell responses. Binding and cellular uptake was improved from 5% of the uncoated nanoparticles to about 53% with mannan coated nanoparticles, again demonstrating the advantage of cell specific binding in targeted delivery systems [75]. To augment anti tumor response through IL-12 gene therapy, mannosylated chitosan nanoparticles are employed for effective endocytosis [76]. Additionally, mannosylated chitosan greatly increase the Ag availability to the macrophages and DCs for better induction of IFN-γ release [77]. Similar to TLRs, ManR also provide a link between innate and adaptive immunity.

Multifactorial nanoparticles used in various studies

Biodegradable nanoparticles are engineered to imitate the surface properties of pathogens to enhance the property of phagocytosis [2,78]. Diwan et al. fabricated nanoparticles from a biodegradable copolymer (PLGA) to deliver cancer Ags to DCs for promoting strong antitumor T cell response [78]. Two Ags, tetanus toxoid and MUC1 [mucin peptide], along with immunomodulators were studied. The Ag was capable of binding to both MHC class I and class II molecules, for activating CD4+ and CD8+ T cells. Two other immunomodulators like MPLA and CpG were studied for effective tumor immunity. MPLA, a ligand for TLR4, was found to have the strongest effect on T cell activation. CpG oligonucleotides following phagocytosis activated TLR9 pathway [78]. Conclusively, Ags delivered in the form of nanoparticles are very effective in T cell activation when compared to soluble Ag [60]. It was noted that Ag presentation by both MHC molecules as well as TLR co stimulatory signaling are required for the potent activation of Ag specific primary T cells, underlining the significance of co-delivery of immunostimulatory molecules [79,80].

Ideally, tumour associated Ag [TSA] specific cytotoxic T cells are generated after the efficient delivery of TSA to APCs, but effective delivery methods are not yet available. Triggering of antitumor immune responses can be achieved using Freund’s incomplete adjuvant, but due to poor tumour specific cytotoxic T cell induction and adverse side effects, a superior method is desirable. A report by Yoshikawa et al. showed that use of biodegradable poly (γ-glutamic acid)-based (γ-PGA) nanoparticles greatly elicited a potent immune response without adverse side effects [81]. The γ-PGA nanoparticles efficiently translocate from endosome into the cytosol for efficient MHC class I Ag presentation. As γ-PGA nanoparticles enhance Ag presentation, CD8+ T cells are promoted to differentiate into cytotoxic T cells, displaying antitumor activity. Hence γ-PGA nanoparticles are used widely in Ag delivery based tumor vaccines [81]. Though the mechanism of immune response has been extensively researched, further investigation regarding the intricate mechanism of γ-PGA nanoparticles in activating the TLR and adaptive immunity is required.

From the age old concept of immunology, both CTLs and NK cells are employed for eliciting antitumor immunity [79]. Exogenous
administration of poly (I:C), a TLR 3 agonist resulted in tumor regression with the activation of NK and CTLs [82]. This method of TLR 3 agonist targeting has been used in a number of different studies for triggering of apoptosis in tumor cells [83,73].

An interesting study by Stone et al. showed that when CD40 and TLR agonists were combined on a single platform they generated a much stronger immune response. Other notable effects of this combinatorial approach resulted in elicitation of potent tumor-specific CD8+ T cells. These findings highlighted the concept of long-lasting immunological memory against tumor through elicitation of effector T cells [84].

Transition of DCs from immunosuppressive stage to immunostimulatory state by immunostimulants is also necessary for effective immunological response. The production of IL-12p70 (IL-12 in a biologically active form with two subunits p35 and p40) is accomplished by synergistic use of two TLR agonists viz poly (I:C) and R-848 for the activation of TLR 3 and TLR 7/8 respectively. 10-100 fold increase in IL-12p70 was noticed upon addition of CD40L. CD40L is used additionally since they enhance CD8 T-cell responses.

Table 1: Functions of various TLRs.

| TLR type | Function |
|----------|----------|
| TLR 1+ TLR 6 | Recognises triacyl peptides [11]. Decreases infection related morbidity and mortality. Necessary for good vaccine response [92]. |
| TLR2 in complex with TLR1 or TLR6 | Lipoproteins and lipopeptides recognition [12,25]. |
| TLR3 | Viral double-stranded RNA recognition and trigger apoptosis directly [13]. |
| TLR4 | Lipopolysaccharide recognition [15]. Germinal centre formation, Ig maturation [93], Neuroinflammation and brain damage [94]. |
| TLR5 | Flagellin recognition [30]. Protect the intestine from commensal bacteria [95]. |
| TLR7 or TLR8 | Single-stranded RNA recognition [17]. Chemoresistance [96]. |
| TLR9 | Microbial DNA recognition [18]. |
| TLR 10 | Only human TLR without any agonist or function [97]. |
| TLR 11 | Preventing infection to internal organs of urinogenital system [20]. |
| TLR 12 | Unknown [21]. |
| TLR 13 | Unknown [21]. |
The core of the magnetic nanoparticle is commonly made of MnO to which ssDNA is incorporated by phosphoramidite. The chromophore [rhodamine] is attached to the polymer chain for imaging. The incorporated ssDNA efficiently elevates TLR 9 pathway for enhancing the antiviral immunity. This novel approach is gaining importance for its optical and magnetic resonance properties [91].

**Conclusions**

Though targeting DCs using TLRs signalling is still in its infancy, it is considered as a very promising technology. Nanodelivery is a suitable method due to rapid and efficient uptake by DCs, and subsequently potent immune responses can be achieved. Co-delivery of cancer associated Ags and TLR agonist loaded nanoparticle has been shown to generate potent immune response. Understanding how these delivery systems affects the mechanism of DCs in stimulating naïve T cells is limited and needs further research. In addition, cellular and molecular mechanisms behind these immune responses are not completely understood, and some immunotherapy studies have led to development of autoimmune conditions in patients. Therefore identification of those molecular triggers involved in innate and adaptive immune systems may revolutionise cancer treatments and vaccine technologies. Once a greater understanding of these signaling pathways has been gained, more effective treatments could include combinations of agents that trigger multiple immunologic pathways.

**Future Perspectives**

Prevention is better than cure, yet it is difficult to prevent certain diseases to which our body is prone. Considerable attention has been given to TLRs over the last decade, furthering our theoretical and mechanistic understanding of innate and adaptive immunity. A current need is to produce safe, immune potentiators or adjuvants using TLRs. The cornea serve as an ideal model for TLR exploration and the future we may see clinicians employing selective TLR ligands as an adjuvant to generate tolerance or utilizing small molecules to modulate TLR signaling in the prevention or treatment of various disorders.

**Executive Summary**

- Dendritic cells induce T cell response and indirectly elicit adaptive immunity.
- Toll like receptor recognise pathogens through pathogen associated molecular patterns.
- IL-1 receptor studies led to the insight of TLR.
- The three phase in which tumour escapes: elimination phase, equilibrium phase and escape phase.
- Human’s express TLR 1-10 gene, TLR 11, TLR 12, TLR 13 gene has been found to explicit in animals.
- TLRs are used as adjuvants to trigger dendritic cell maturation, leukocyte migration, release of chemokines and cytokines for enhanced immunity.
- Corneal angiogenesis studies are conducted in rabbit eyes. Cornea express most of the TLRs.
• Corneal haziness can be sorted out in humans by use of TLRs in combination with nanoparticles.

• Nanoparticle drugs conjugated with PEG follows EPR effect and found to be efficient in combating tumour.

• Viral immunity is attained by employing TLRs. Even the dreadful virus HIV is combated using TLR ligands.

Acknowledgements

The work was supported by the grants from Institute of Biotechnology, Institute for Technology & Research Innovation and the Australia-India Strategic Research Fund (AISRF) Australia.

References

1. Ngoma T (2006) World health organisation cancer priorities in developing countries. Ann Oncol 17.

2. Lasker, MV, Nair SK (2006) Intracellular TLR signaling: A structural perspective. J Immunol 177: 11-16.

3. Netea MG, Van der Graaf C, Van der Meer JW, Kullberg BJ (2004) Toll-like receptors and the host defend against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol 75: 749-755.

4. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, et al. (2011) Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A 108: 5354-5359.

5. Wells JM, Rossi O, Meijerink M, Van Baarlen P (2011) Epithelial crosstalk at the microbiota mucosal interface. Proc Natl Acad Sci U S A; 108: 4607-4614.

6. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr (1997) A human homologue of the drosophila toll protein signals activation of adaptive immunity. Nature 388: 394-397.

7. West AP, Shadel GS, Ghosh S (2011) Mitochondria in innate immune response. Nat Rev Immunol 11: 389-402.

8. Neill LA, Bowie AG (2007) The family of five: TIR domain containing adaptors in toll like receptor signaling. Nat Rev Immunol 7: 353-364.

9. Su B (2005) Linking stress to immunity? Nat Immunol 6: 541-542.

10. Schmidt C (2006) Immune system’s tolls like receptors have good opportunity for cancer treatment. J Natl Cancer Inst 98: 574-575.

11. Huang Y, Temperley ND, Ren L, Smith J, Li N, et al. (2011) Molecular evolution of the vertebrate TLR 1 gene family - a complex history of gene duplication, gene conversion, positive selection and co-evolution. BMC Evol Biol 11:149.

12. Azuma M, Sawahata R, Akao Y, Ebihara T, Yamazaki S, et al. (2010) The membrane receptor signal sequence of diacyl lipopeptides determines dendritic cell TLR2 mediated NK activation. Plos One 5: 12550.

13. Lee HK, Dunzendorfer S, Soldau K, Tobias PS (2006) Double stranded RNA mediated TLR 3 activation is enhanced by CD14. Immunity 24: 153-63.

14. Frasellini ME, Tarusio D, Chobazu-Pécait V, Bussu N, So A (2005) TLR 2 modulates inflammation in zymosan induced arthritis in mice. Arthritis Res Ther 7: 370-379.

15. Beutler B (2000) TLR 4: central component of the sole mammalian LPS sensor. Cell 100: 20-22.

16. Petrof EO, Musch MW, Ciancio M, Sun J, Hobert ME, et al. (2008) Flagellin toll like receptors and the host defend against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol 75: 749-755.

17. Matijevic T, Pavlic J (2010) Toll like receptors: cost or benefit for cancer?. Curr Pharm Des16: 1081-1090.

18. Bauer S, Kirschning CJ, Hacker H, RedeckeV, Hausmann S, et al. (2001) Human TLR 9 confers responsiveness to bacterial DNA via species specific CpG motif recognition. Proc Natl Acad Sci U S A 98: 9237-9242.

19. Yeo SJ, Gravis D, Yoon JG, Yi Ak (2009) Myeloid differentiation factor88 dependent transcriptional regulation of cyclooxygenase 2 expression by CpG DNA. J Biol Chem 278: 22563-22573.

20. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, et al. (2004) A toll like receptor that prevents infection by uropathogenic bacteria. Science 303: 1522-1526.

21. Kawai T, Akira S (2009) The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 21: 317-337.

22. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G (2009) MF59- adjuvanted versus non adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27: 6959-6965.

23. Garcon N, Wetten Dorff M, Van Mechelen M (2011) Role of ASC4 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther 11: 667-677.

24. Méndez-Samperio P, Belmont L, Miranda E (2008) Mycobacterium bovis BCG toll like receptors 2 and 4 co-operation increases the innate epithelial immune response. Arch Med Res 39: 33-39.

25. Shin DM, Yuk JM, Lee HM, Lee SH, Son JW, et al. (2010) Mycobacterial lipoprotein activates autophagy via TLR2/1/CD14 and a functional vitamin D receptor signaling. Cell Microbiol 12: 1648-1665.

26. Yamazaki S, Okada K, Maruyama A, Matsumoto M, Yagita H, et al. (2011) TLR 2 dependent induction of IL-10 and Foxp3 CD25+ CD4+ regulatory T cells prevents effective anti tumor immunity induced by Pam2 lipopeptides in vivo. Plos One 6: 18833.

27. Jasani B, Navabi H, Adams M (2009) Ampligen: A potential toll like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27. 3401-3404.

28. Fujimoto C, Nakagawa Y, Ohara K, Takahashi H (2004) Polyribosinosine polyribocytidylic acid [poly(c)][/poly(c)]TLR3 signaling allows class I processing of exogenous protein and induction of HIV specific CD8+ cytotoxic T lymphocytes. Int Immunol 16: 55-63.

29. Kumar H, Koyama S, Iishi KJ, Kawai T, Akira S (2008) Cutting edge: co-operation of IPS-1 and TRIF dependent pathways in poly IC- enhanced antibody production and cytotoxic T cell responses. J Immunol 180: 683-687.

30. Demento SL, Sieffert AL, Bandyopadhyay A, Sharp FA, Fahey TM (2011) Pathogen associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol 29: 294-306.

31. Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, et al. (2011) Induction of a potent immune response in the elderly using the TLR 5 agonist, flagellin with a recombinant hantagglutinin influenza flagellin fusion vaccine (VAX125, STF2.HA1 S1). Vaccine 29: 4897-4902.

32. Letran SE, Lee S, Aftl SM, Unnata S, Akira S, et al. (2011) TLR 5 functions as an endocytic receptor to enhance flagellin specific adaptive immunity. Eur J Immunol 41: 29-38.

33. Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Amrbenberger F, et al. (2003) The toll like receptor 7 (TLR 7) specific stimulus loxoribine uncovers a strong relationship within the TLR 7, 8 and 9 subfamily. Eur J Immunol 3: 1522-1526.

34. Phase I clinical trial of VTX-2337, a novel TLR 8 agonist, in patients with advanced solid tumors. American Society of Clinical Oncology Annual Meeting [June 2011].

35. Daubenberger CA (2007) TLR 9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr Opin Mol Ther 9: 45-52.

36. Krieg AM (2008) Toll like receptor 9 agonists in the treatment of cancer. Oncogene 27: 161-167.

37. Jalkonen I, Sareneva T, Pirhonen J, Ronni T, Melen K, et al. (2001) Molecular pathogenesis of influenza A virus infection and virus induced regulation of cytokine gene expression. Cytokine and Growth Factor Rev 12: 171-180.

38. Takeda K, Akira S (2004) TLR signaling pathways. Semin Immunol 16: 3-9.

39. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhrhardt PF, et al. (2001) Lipopolysaccharide stimulates the MyD88 independent pathway and results in activation of IFN-α/β-regulatory factor 3 and the expression of a subset of lipopolysaccharide inducible genes. J Immunol 167: 5887-5894.

40. Yamamoto M, Takeda K, Akira S (2004) TLR domain containing adaptors define the specificity of TLR signaling. Mol Immunol 40: 861-868.
41. O'Neill LA, Sheedy F, McCoy CE (2011) MicroRNAs: the fine tuners of toll like receptor signaling. Nat Rev Immunol 11: 163-175.

42. Campos-Mollo E, Pérez-Santanton JJ, Lledo-Riquelme M, Ortega Pastor E, Alós JL (2006) New corneal neo-vascularisation model in rabbit for angiogenic research. Ophthalmic Res 45: 135-41.

43. Kumar A, Yu FS (2006) Toll like receptors and corneal innate immunity. Curr Mol Med 6: 327-337.

44. Matsuoka M, Petersson M, Lenkri R, Taupin JL, Magnunsson I, et al. (1995) Alteration in the signal transducing molecules of T cells and NK cell in colorectal tumor infiltrating gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61: 765-772.

45. Nassif KF. Interactions of the eye. Little Brown and Company 1996.

46. Redfern RL, McDermott AM. Toll like receptors in ocular surface disease. Exp Eye Res 90: 679-687.

47. Pearlman E, Johnson A, Adhikary G, Sun Y, Chinnery HR (2008) Toll like receptors at the ocular surface. The Ocular Surface 6: 1.8-16

48. Huang X, Du W, McClelland SA, Barrett RP, Hazelett LD (2006) TLR 4 is required for host resistance in Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 47: 4910-4916.

49. Tallant T, Deb A, Kar N, Lupica J, de Veer M, et al. Flagellin acting via TLR 5 is the major activator of key signaling pathways leading to NF-kB and proinflammatory gene program activation in intestinal epithelial cells. BMC Microbiol 4: 33.

50. Love W, Dobbs N, Tabor L, Simecka JW (2010) Toll like receptor 2 (TLR 2) plays a major role in innate resistance in the lung against murine mycoplasma. PLoS one 5: 10739.

51. Wagner H (2002) Interactions between bacterial CpG-DNA and TLR 9 bridge innate and adaptive immunity. Curr Opin Microbiol 5: 62-69.

52. Ueta M, Kinoshita S (2010) Ocular surface inflammation mediated by innate immunity. Eye Contact Lens 36: 269-281.

53. Ferguson I, Daehnel K, Hise AG, Sun Y, Carlson E, et al. (2007) Toll-Like Receptor 2 Regulates CXC Chemokine Production and Neutrophil Recruitment to the Cornea in Onchocerca volvulus/ Wolbachia-Induced Keratitis. Infect Immun 75: 5908-5915.

54. Sack R, Sathe S, Beaton AR, McNamara N, Fleiszig S, et al. (2009) Protein Array Characterization of Bioactive Proteins Secreted By Immortalized Human Corneal Epithelium in Response to Pseudomonas Constituents. Curr Eye Res 34: 92-98.

55. Myrna KE, Pot SA, Murphy CJ (2009) Meet the corneal myofibroblast: the role of myofibroblast transformation in corneal wound healing and pathology. Vet Ophthalmol 12: 25-27.

56. Tabbara KF (2001) Blinding trachoma: the forgotten problem. Br J Ophthalmol 85: 1397-1399.

57. Chen KH, Kuang TM, Hsu WM (2001) Serratia marcescens corneal ulcer as a complication of orthokeratology. Am J Ophthalmol 132: 257-258.

58. Taylor HR, Fox SS, Xie J, Dunn RA, Arnold MR, et al. (2010) The prevalence of Trachoma in Australia: the national indigenous eye health survey. Med J Aust 192: 248-253.

59. Ueta M (2008) Innate Immunity of the Ocular Surface and Ocular Surface Inflammatory Disorders. Cornea 27: 31-40.

60. Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future prospects. The FASEB J 19: 119-131.

61. Byrne JD, Betancourt T, Brannon Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60: 1615-1626.

62. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380-384.

63. Choi Y, Kwak J, Park JW (2010) Nanotechnology for Early Cancer Detection. Sensors 10: 428-455.

64. Modi S, Jain PJ, Domb AJ, Kumar N (2006) Exploiting EPR in polymer drug conjugate delivery for tumor targeting. Curr Pharm Des 12: 4785-4796.

65. Pirillo KF, Chang EH (2008) Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends biotechnol 26: 552-558.

66. Lammers T, Henrikkink WE, Storm G (2008) Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99: 392-397.

67. Torchilin VP (2010) Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 197: 3-53.

68. Yokoyama M (2005) Drug targeting with nano-sized carrier systems. J Artif Organs 8: 77-84.

69. Kanwar JR, Mohan RR, Kanwar RK, Roy K, Bawa R et al. (2010) Application of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine (Lond) 5: 1435-1445.

70. Beck G, Habicht G (1998) Immunity and invertebrate. Sci Am 275: 60-63

71. Pham TN, Hong CY, Min JJ, Rhee J, Nguyen TA, et al. (2010) Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist. Exp Mol Med.

72. Hamdy S, Molavi O, Haddadi A, Alshamsan A, Gobbi Z, et al. (2008) Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 26: 5046-5057.

73. Conforti R, Ma Y, Morel Y, Paturel C, Termre M, et al. (2010) Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands. Cancer Res 70: 490-500.

74. Cui Z, Hsu CH, Mumper RJ (2003) Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev Ind Pharm 29: 689-700.

75. Yu W, Liu C, Liu Y, Zhang N, Xu W, et al. (2010) Mannan-Modified Solid Lipid Nanoparticles for Targeted Gene Delivery to Alveolar Macrophages. Pharm Res 27: 1594-1596.

76. Kim TH, Jin H, Kim HW, Cho M, Cho CS, et al. (2006) Mannosylated chitosan nanoparticle- based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol Cancer Ther 5: 1723.

77. Kim TH, Nah JW, Cho MH, Park TG, Cho CS, et al. (2006) Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles. J Nanosci Nanotechnol 6: 2796-2803.

78. Diwan M, Elmanchili P, Lane H, Gainer A, Samuel J (2003) Biodegradable Nanoparticle Mediated Antigen Delivery to Human Cord Blood Derived Dendritic Cells for Induction of Primary T Cell Responses. J Drug Target 11: 495-507.

79. Akira S, UematsuS, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124: 783-801.

80. You Q, Cheng L, Ju C (2010) Generation of T cell responses targeting the reactive metabolite of halothane in mice. Toxicol Let 194: 79-85.

81. Yoshikawa T, Okada N, Oda A, Matsuo K, Matsuo K, et al. (2008) Nanoparticles for Targeted Gene Delivery. J Drug Target 16: 197-206.

82. Yokoyama M (2005) Drug targeting with nano-sized carrier systems. J Artif Organs 8: 77-84.

83. Koida S, UematsuS, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124: 783-801.

84. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, et al. (2007)Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907.

85. Stone GW, Barzee S, Snarksy V, Santucci C, Tran B, et al. (2009) Nanoparticle-delivered multimeric soluble CD40L DNA combined with toll-like receptor agonists as a treatment for melanoma. PLoS One 4: 7334.

86. Bekeredian-Ding I, Jego G (2009) Toll-like receptors – sentries in the B-cell response. Immunology 128: 311-323.
86. Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, et al. (2005) TLR-7-, -8-, and -9-Mediated Induction of IFN-alpha/beta and -lamba Is IRAK-4 Dependent and Redundant for Protective Immunity to Viruses. Immunity 23: 465-478.

87. Sokolova V, Knuschke T, Koflun A, Buer J, Eppe M, et al. (2010) The use of calcium phosphate nanoparticles encapsulating toll like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials 31: 5627-5633.

88. De Hase W, De Koker S, Pollard C, Atkinson D, Vielghue E, et al. (2010) Polyelectrolyte Capsules-containing HIV-1 p24 and Poly I:C Modulate Dendritic Cells to Stimulate HIV-1-specific Immune Responses. Mol Ther 18: 1408-1416.

89. Lima GK, Zoliní GP, Mansur DS, Freire Lima BH, Wischhoff U, et al. (2010) Toll-Like Receptor (TLR) 2 and TLR9 Expressed in Trigeminal Ganglia are Critical to Viral Control During Herpes Simplex Virus 1 Infection. Am J Pathol 177: 2433-2445.

90. Morrison LA, Zhu L, Thebeau LG (2001) Vaccine-Induced Serum Immunoglobulin Contributes to Protection from Herpes Simplex Virus Type 2 Genital Infection in the Presence of Immune T Cells. J Virol 75: 1195-204.

91. Shukoor MJ, Natalio F, Tahir MN, Wiens M, Tarantola M, et al. (2009) Pathogen-Mimicking MnO Nanoparticles for Selective Activation of the TLR9 Pathway and Imaging of Cancer Cells. Advanced Functional Materials 19: 3717-3725.

92. Van Duin D, Mohanty S, Thomas V, Ginter S, Montgomery RR, et al. (2007) Age-Associated Defect in Human TLR-1/2 Function. J Immunol 178: 970-975.

93. Pasare C, Medzhitov R (2005) Control of B-cell responses by Toll-like receptors. Nature 438: 364-368.

94. Alfonso-Loeches S, Pascual Lucas M, Blanco AM, Sánchez-Vera I, Guerri C, et al. (2010) Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage. J Neurosci 30: 8285-8295.

95. Bambou JC, Giraud A, Menrad S, Begue B, Rakotosobe S, et al. (2004) In Vitro and ex Vivo Activation of the TLR5 Signaling Pathway in Intestinal Epithelial Cells by a Commensal Escherichia coli Strain. J Biol Chem 279: 42984-42992.

96. Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, et al. (2010) Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clinical Invest 120: 1285-1297.

97. Park HJ, Hahn W, Suh J, Kim M, Kang SW, et al. (2011) Association between toll-like receptor 10 (TLR10) gene polymorphisms and childhood IgA nephropathy. Eur J Pediatr 170: 503-509.